Health – MSD
Big shot
A
How does the trivalent vaccine protect1 against these diseases in Atlantic salmon? In pancreas disease the vaccine reduces
the clinical signs (heart lesions and pancreas lesions), viremia, viral shedding and mortality from infection. It is shown to reduce mortality from infections with infectious pancreatic necrosis (IPNV) and also reduce mortality from infections with furunculosis (Aeromonas salmonicida subsp. salmonicida).
34
New three-in-one vaccine offers signifi cant health and management benefi ts, says MSD
QUAVAC® PD3 The new single shot vaccine protecting1 salmon against pancreas disease, furunculosis and infectious pancreatic necrosis (IPN) in
the UK. Following the industry launch of AQUAVAC PD3 to vets and producers by MSD Animal Health UK Aquaculture (known as Merck An- imal Health in the United States and Canada) in May 2015 salmon producers in the UK and Ireland are now vaccinating with the new trivalent. By vaccinating salmon against the three most common and damaging diseases the new single shot vaccine offers immedi- ate and significant health and management benefits. Here, Dafydd Morris, business manager aq-
uaculture for MSD Animal Health UK, provides further background on the release of the new vaccine and highlights the company’s strategy of continuous development and customer support.
Can you confirm the three specific diseases the vaccine protects1 against? The new trivalent vaccine protects1 against
pancreas disease (PD), furunculosis and infectious pancreatic necrosis (IPN). These diseases can severely impact fish health and as a result are extremely costly to producers when salmon are unprotected and infected.
Top: Vaccinati on Above: Dafydd Morris business manager aquaculture for MSD Animal Health UK
in vaccinati on man hours and associated labour
“There is direct cost saving ”
For what period of time will the vaccine provide immunity for salmon? Laboratory tests and field trials have demonstrated that AQUAVAC PD3 provides at least 16 months’ duration or immunity against furun- culosis and at least 15 months against pancreas disease. In addition, trials have demonstrated a reduction in shedding of salmon pancreas disease virus. Duration of immunity against mortality due to IPNV infection has been demonstrated at four months in the field.
In addition to the direct advantages for fish health can you confirm how welfare can also be improved through vaccinating with the trivalent vaccine? Prior to AQUAVAC PD3, two separate injections were administered
to protect fish against pancreas disease and other major salmon diseases. Multiple injections not only increase the workload for fish farmers, but can negatively impact fish welfare and growth due to increased handling and extra feed withdrawal periods. With the new trivalent only requiring one single vaccination there is the direct cost saving in vaccination man hours and associated labour. These factors combined can provide demonstrable cost savings.
Was AQUAVAC PD3 trialed in the UK prior to launch? In addition to the statutory testing as part of the product licence
requirements, the company undertook substantial field trials across a number of sites. The results of these trials proved the efficacy of the
www.fishfarmer-magazine.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68